Sexual health
Kisspeptin
The master upstream regulator of the reproductive hormone axis, more recently studied for direct effects on sexual and emotional brain processing, not just downstream hormone levels.
Investigational Sexual health
- Full name
- Kisspeptin (KP-10 and related fragments, encoded by the KISS1 gene)
- Also known as
- KP-10, Metastin (older name)
- Regulatory status
- Research/investigational compound. Not FDA-approved for any indication, though it has been used in legitimate clinical research settings (including UK academic trials on sexual response and reproductive hormone stimulation) more than most 'research chemical' peptides.
Origin
The peptide product of the KISS1 gene, discovered originally in cancer-metastasis-suppression research (hence its older name metastin) before its essential role triggering puberty and regulating the reproductive hormone axis was identified.
Mechanism
Kisspeptin neurons in the hypothalamus sit directly upstream of GnRH neurons: kisspeptin release triggers GnRH release, which drives LH/FSH release from the pituitary and ultimately testosterone/estrogen production. Beyond this classic reproductive-axis role, functional brain imaging studies from Imperial College London show kisspeptin administration modulates activity in brain regions tied to sexual and romantic processing directly, effects beyond downstream hormone stimulation.
Research summary
Evidence
One of the more legitimately academically researched compounds in the sexual-health category, with published human trials, including controlled fMRI studies, showing kisspeptin administration increases sexual and romantic brain activity in men, and separately increases LH pulsatility in reproductive-axis research. Also studied as a potential fertility-treatment adjunct for triggering ovulation in IVF protocols. None of this has translated into an approved, marketed drug; it remains a research and early clinical-trial compound.
Evidence tier: Investigational — see the methodology note for how this is assessed.
Citations
- Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy — Abbara et al. 2015
- A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial — Abbara et al. 2017
- The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function — Owens et al. 2018
Reported benefits
- Research-documented increase in reproductive hormone axis activity (LH, and downstream testosterone/estrogen)
- Academic research (not yet self-experimentation-community-level evidence) suggesting direct effects on sexual/romantic brain processing
- Interest in fertility contexts (IVF ovulation triggering) is a genuine, ongoing area of clinical research
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Subcutaneous injection (self-experimentation, extrapolated from research protocols) | Research studies commonly use kisspeptin doses in the range of a few hundred nanomoles to low micrograms-per-kg, given as single doses or short infusions in controlled research settings — very different from the community-sourced 'daily dosing' patterns common for other peptides, since kisspeptin's research use has mostly been in acute, single-administration study designs rather than chronic self-dosing protocols. |
Side effects
- Generally well tolerated in the research trials conducted to date
- Because it sits at the top of the reproductive hormone cascade, theoretical concern about disrupting normal hormonal feedback loops with chronic/frequent dosing outside a controlled research context — this hasn't been well studied
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Less mainstream than PT-141 in self-experimentation communities. Interest tends to come from people who've read the Imperial College London fMRI research rather than from a large base of self-reported user experience, the opposite pattern from something like BPC-157: the academic research is ahead of the community-use track record.
Related peptides
Mixing compatibility
Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.